Acadia Pharmaceuticals Inc.

Neuronano Ab

Nycomed Imaging As

Amersham Health As

Spago Imaging Ab

Nauronano Ab

Spago Nanomedical Ab

Fredrik Ek

Jens Schouenborg

Per Petersson

Nils Danielsen

Jenny Eriksson Linsmeier

Roger Olsson

Jörgen Ohlsson

Torsten Almen

Oskar Axelsson

Rodrigo Petoral, Jr

Petter Lauritzson

Lars Goran Wistrand

Jr Petoral Rodrigo M

Rodrigo M Petoral Jr

A medical microelectrode includes an elongate electrode body including a tip section, a main body section and, optionally, a coupling section. The tip section, the main body section and, optionally, the coupling section are embedded in a first electrode matrix element, which is substantially rigid, biocompatible and soluble or biodegradable in a body fluid. Additionally the microelectrode includes a dissolution retarding layer on the first electrode matrix element and/or a second electrode matrix element disposed between the first electrode matrix element and the electrode. Upon dissolution or biodegradation of the first electrode matrix element a drug comprised by the first electrode matrix element or the second electrode matrix element is released into the tissue. Also disclosed are bundles and arrays of the electrodes and their use.

Microelectrode and multiple microelectrodes

A medical microelectrode includes an elongate electrode body including a tip section, a main body section and, optionally, a coupling section. The tip section, the main body section and, optionally, the coupling section are embedded in a first electrode matrix element, which is substantially rigid, biocompatible and soluble or biodegradable in a body fluid. Additionally the microelectrode includes a dissolution retarding layer on the first electrode matrix element and/or a second electrode matrix element disposed between the first electrode matrix element and the electrode. Upon dissolution or biodegradation of the first electrode matrix element a drug comprised by the first electrode matrix element or the second electrode matrix element is released into the tissue. Also disclosed are bundles and arrays of the electrodes and their use, which may be positioned on a face of a solid support.

Disclosed herein are nanostructures comprising a polymeric framework comprising at least five geminal bisphosphonate groups, wherein the geminal bisphosphonate groups independently of each other are incorporated as &#x2014;RRC(P&#x2550;O(OR)(OR)), wherein Rand Rare independently selected from the group consisting of a negative charge, H, alkyl and aryl, and wherein at least one of Rand Ris a group connected to the polymeric framework with the proviso that when only one of Rand Ris such a connected group, the other of Rand Ris either a group being able to connect to the polymeric framework, or the residue of such a group, or selected from the group consisting of H, OH, ORand R, wherein Ris a lower alkyl. The polymeric framework may comprise manganese ions. Disclosed are also methods for producing such manganese containing nanostructures, compositions comprising such manganese containing nanostructures and use of such manganese containing nanostructures, i.a. as MRI contrasting agents.

Manganese comprising nanostructures

Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, methods of synthesizing the analogs; and methods of using the analogs for treating neuropsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.

[object Object]

Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuropsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.

Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.

Contrast media

A process for the preparation of an allylic aromatic compound in which an aromatic amine is reacted first with a nitrite and then with an allylic olefin having an eliminatable terminal substituent. Novel allylic derivatives of disubstituted benzene compounds are also described.

Growing community of inventors

Lund, Sweden

Fredrik Ek